T98G: Difference between revisions
T98G glioblastoma cells |
No edit summary |
||
| Line 9: | Line 9: | ||
==References== |
==References== |
||
{{Reflist}} |
{{Reflist}} |
||
==External links== |
|||
*[https://web.expasy.org/cellosaurus/CVCL_0556 Cellosaurus entry for T98G] |
|||
[[Category:Human cell lines]] |
[[Category:Human cell lines]] |
||
Revision as of 09:48, 4 May 2018
T98G is a glioblastoma cell line used in brain cancer research and drug development.[1]
Characteristics
The T98G cell line was derived from a 61-year-old human male and has a hyperpentaploid chromosome count with a modal number ranging from 128 to 132.[2] The cells are not tumorigenic in mice, but do proliferate with proper anchorage in cell culture.[1] T98G cells are known for having high expression of the ACTA2 gene, which is involved in cell motility and structure.[3] T98G cells are polyploidy variants of the parent T98 cell line, and can stay in the G1 phase of the cell cycle under stationary conditions.[1]
Use in Research
T98G cells have been investigated along with A172 cells for drug cytotoxicity[3], and were found to be resistant to cisplatin, with larger cytotoxic effects induced by viral-mediated production of the p53 protein.[4] T98G culturing and cryopreservation protocols are published by the ATCC.[5]
References
- ^ a b c Stein, Gretchen (April 1979). "T98G: An anchorage‐independent human tumor cell line that exhibits stationary phase G1 arrest in vitro". Journal of Cellular Physiology. 99 (1): 43–54. doi:10.1002/jcp.1040990107.
- ^ "T98G". ATCC. Retrieved 3 May 2018.
- ^ a b Kiseleva, L; et al. (September 2016). "A172 and T98G cell lines characteristics". Cell and Tissue Biology. 10 (5): 341–348. doi:10.1134/S1990519X16050072.
- ^ Park, Jong; Kim, Tae (2002). "Cisplatin-Induced Apoptosis by Cisplatin in Human Glioblastoma Cell Line". Journal of Korean Neurosurgical Society. 31 (6): 574–584.
- ^ "SOP: Thawing, Propagation and Cryopreservation of NCI-PBCF-CRL1690 (T98G)" (PDF). ATCC. Retrieved 3 May 2018.